Centiva Capital’s Blueprint Medicines BPMC Stock Holding History

Centiva Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,935	Closed	-$441K	–	1162
2020 Q4	$441K	Buy	+3,935	New	+$415K	0.02%	494

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Centiva Capital's BPMC Position: Q1 2021 in Review

Centiva Capital sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 3,935 shares — an estimated $441K sold.

Centiva Capital first reported a position in BPMC in Q4 2020 and held it in 1 quarter. The position peaked at $441K in Q4 2020. 264 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

Centiva Capital reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
Centiva Capital sold 3,935 Blueprint Medicines shares in Q1 2021, an estimated $441K.
Centiva Capital first reported a position in Blueprint Medicines in Q4 2020 and held it in 1 quarter.
Centiva Capital's Blueprint Medicines position peaked at $441K in Q4 2020.
264 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Centiva Capital's 13F filing for Q1 2021, filed 17 May 2021.